Modulation of the immune response and control of tumour spread by a new synthetic compound.
A small molecular weight biofunctional polymer, NED 137, has been investigated for its anti-neoplastic effect. Through its effect on the immune system, particularly the induction of B cell differentiation to antibody producing cells, this synthetic compound can retard tumour growth and prevent the development of distant metastases. Reactivity to tumour developed following administration of the NED 137. No toxicity has been observed. The polymer NED 137 is now being tested in phase I and phase II clinical trials.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000951:Antigens, Neoplasm; D008175:Lung Neoplasms / Q000556:secondary; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D011108:Polymers / Q000627:therapeutic use*; D051381:Rats; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D011108:Polymers; C022084:carboxyimamidate